Estrogen receptor α and β in uterine fibroids: a basis for altered estrogen responsiveness by Bakas, Panagiotis et al.
ARTICLE IN PRESSCLINICAL ARTICLEReceived
Supported
Reprint req
Foundat
30-210-
0015-028
doi:10.10Estrogen receptor a and b in uterine fibroids: a basis
for altered estrogen responsiveness
Panagiotis Bakas, M.D.,a Angelos Liapis, M.D.,a Spiros Vlahopoulos, Ph.D.,b Maria Giner, M.D.,a
Stella Logotheti, B.Sc.,b Georgios Creatsas, M.D.,a Aggeliki K. Meligova, B.Sc.,c Michael N. Alexis,
Ph.D.,b,c and Vassilis Zoumpourlis, Ph.D.b
a 2nd Department of Obstetrics and Gynaecology, Aretaieio Hospital, University of Athens; b Biomedical Application Unit; and
c Molecular Endocrinology Programme, Institute of Biological Research and Biotechnology, National Hellenic Research
Foundation, Athens, Greece
Objective: To investigate the relative expression and the DNA-binding status of estrogen receptors a and b in
fibroids and normal myometrial tissue to explore the molecular basis of altered estrogen responsiveness of
leiomyomas.
Design: Biopsy samples from uterine fibroids and adjacent normal myometrial tissue at the follicular phase of the
menstrual cycle.
Setting: Aretaieio University Hospital and the National Hellenic Research Foundation, Athens, Greece.
Patient(s): Thirty-five patients who underwent hysterectomy or myomectomy because of myoma symptoms.
Intervention(s): None.
Main Outcome Measure(s): Deoxyribonucleic acid–binding status of estrogen receptors a and b.
Result(s): The level of messenger RNA expression of estrogen receptor a and b and the level of estrogen receptor
as a whole are increased on average to a similar extent in leiomyomas compared with normal myometrium. Oc-
casionally, however, estrogen receptor a is disproportionately increased in leiomyomas, and this appears to in-
crease the amount of estrogen receptor a that binds to the estrogen-responsive element of estrogen target genes
as homodimer rather than as heterodimer with estrogen receptor b.
Conclusion(s): The estrogen receptor a–to–estrogen receptor b expression ratio rather than the individual expres-
sion levels determines the fraction of DNA-binding homodimers of estrogen receptor a and possibly the growth
potential of myomas. (Fertil Steril 2008;-:-–-. 2008 by American Society for Reproductive Medicine.)
Key Words: Uterine myomas, estrogen receptor alpha, estrogen receptor beta, myometrium, fibroidsUterine leiomyoma (also known as myoma or fibroid) is the
most common benign gynecologic tumor and is present in at
least 20% of women at reproductive age and in 40% to 50%
of women older than 40 years of age (1). It is estimated that
<50% of uterine myomas produce symptoms, and they are
usually discovered by clinical examination. Although the
etiology of uterine fibroids is unknown, their development is
considered to be estrogen dependent, because they have the
ability to enlarge during pregnancy and to shrink during men-
opause, ovariectomy, and other hypoestrogenic conditions
(2–4). Aromatase P450 is often overexpressed in myomas,
causing in situ synthesis of estrogen to increase, and this is
believed to contribute to the growth of leiomyomas (5). Recent
studies therefore continue to focus on the role of estrogen
receptor (ER) in the pathogenesis of leiomyomas (6).May 22, 2007; revised and accepted September 10, 2007.
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16/j.fertnstert.2007.09.019 Copyright ª2008 American SEstrogens act mainly through two ER subtypes, ERa
and ERb, which function as ligand-dependent regulators
of transcription in a manner that depends on the selection
of cognate cofactors provided by the cell and the structure
of the ER target gene promoter, as well as that of the ligand
(7–9). The two forms of ER bind to DNA enhancer elements
(estrogen-responsive elements [EREs]) or to other transcrip-
tion factors (e.g., Activator Protein 1 [AP1]) in the promoter
of ER target genes as a heterodimer, as well as homodimers
(10, 11). Estrogen receptor a and ERb exhibit significant ho-
mology in the DNA-binding domain and the ligand-binding
domain, where receptor dimerization functions are known
to reside. However, the ligand-binding specificity and the
transcriptional activity of the two forms of ER are known
to differ substantially (8, 9). In fact, it has been reported
that ERa and ERb have opposite effects on AP1 sites and
that they probably have different roles as regards regulation
of AP1-dependent genes, including genes involved in the
control of cell growth and viability (12). In the mammary
gland, ERa and ERb are pivotal for tissue development and
terminal differentiation, respectively (13, 14). In line withFertility and Sterility Vol.-, No.-,- 2008 1
ociety for Reproductive Medicine, Published by Elsevier Inc.
ARTICLE IN PRESSthis, 17b-E2 (hereafter referred to as E2) has been reported to
promote the growth of immortalized mammary cells through
ERa and inhibit it through ERb (15). In mammary hyperpla-
sia of the usual type, it is the ERa-to-ERb ratio rather than the
individual receptor amounts that reportedly is associated with
the risk that this lesion will develop into invasive carcinoma
(16). Work with ERa-positive breast cancer cells engineered
to express increasing amounts of ERb has shown that, al-
though ERb could regulate genes that are not targeted by
ERa alone, it increasingly affected genes regulated by ERa
as well, although nearly half of ERa target genes were not af-
fected even when the level of ERb was set to be much higher
than that of ERa (17). Notably, however, key genes involved
in the hormonal control of cell proliferation and apoptosis
were among those of ERa target genes that were affected
by ERb, implying that the ERa-to-ERb expression ratio
could influence tumor cell growth and consequently breast
cancer prognosis and treatment as well (17).
Although endothelial and connective tissue cells of leio-
myomas and normal myometrium express only ERb, smooth
muscle cells express both ER subtypes (18). Whether and
how the ERa-to-ERb expression ratio could influence the
estrogen-dependent development of leiomyomas is not
known presently. Several studies have demonstrated that
the level of expression of ERb messenger RNA (mRNA) in
both leiomyomas and normal myometrium is lower than
that of ERa (19–22). However, there is conflicting evidence
as regards the level of ERa mRNA in the leiomyomas com-
pared with the adjacent myometrium, with some studies
reporting an increase in the diseased tissue compared with
normal (19) and others reporting no change (20, 22). There
is also conflicting evidence as regards the relative abundance
of the two forms of ER in the fibroids and how this could
impact fibroid response to hormonal therapy, because some
studies report that the ERa-to-ERb ratio is higher in the
diseased tissue compared with normal (22), whereas others
report an increase in the ERa-to-ERb ratio after treatment
with a GnRH analogue (21). In addition, it has been reported
that the levels of ERa and ERb in myometrial cells change
during the menstrual cycle and that the patterns of changes
are similar (4). The present study aims at estimating mRNA
and protein levels as compared with the DNA-binding
activities of two ER subtypes in leiomyomas and normal
myometrium during the follicular phase of the menstrual
cycle.MATERIALS AND METHODS
Patient Selection and Tissue Collection
Biopsy samples of uterine leiomyomas and adjacent myome-
trium were taken from 35 women at the follicular phase of the
menstrual cycle (between day 5 and day 9). Dating of
endometrium was performed with use of Noyes criteria
(23). The criterion for inclusion in the study was pending
operation for hysterectomy or myomectomy because of
subfertility, menorrhagia, or other bothering myoma symp-
toms. Criteria for exclusion from the study were adenomyo-2 Bakas et al. Estrogen receptors a and b in fibroidssis, malignancy, or hormonal therapy given within 3 months
before operation. Selected patients were subjected to a com-
plete preoperative workup to exclude any other known possi-
ble cause of their problem. All specimens originated from
2nd Department of Obstetrics and Gynaecology, Aretaieio
Hospital, School of Medicine, University of Athens, and
were examined by the same histopathologists. The study
took place with the permission of the local ethics committee.
All patients gave informed consent for participating in the
study.Ribonucleic Acid Quantification
Ribonucleic acid extraction Total RNA was isolated from
normal and pathologic (leiomyoma) myometrial samples
with use of TRIzol (GIBCO BRL, Grand Island, NY) accord-
ing to the manufacturer’s instructions, and RNA concentra-
tion of the samples was measured with use of a U-2000
spectrophotometer (Hitachi, Tokyo, Japan).
Complementary DNA synthesis Messenger RNA transcrip-
tion into complementary DNA (cDNA) was performed with
use of 2 mg of total RNA and SuperScript ribonuclease
(RNase) H–reverse transcriptase (Invitrogen, Carlsbad,
CA), according to manufacturer’s instructions.
Polymerase chain reaction Estrogen receptor a and ERb
mRNA levels were assessed with use of semiquantitative
multiplex reverse transcriptase–polymerase chain reaction
(RT-PCR) as previously described (24). Estrogen receptor
a and ERb cDNA fragments were coamplified with a larger
reference cDNA fragment of glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) (25). The ratio of the relative
amounts of the amplified products in myoma samples is taken
to reflect the relative amounts of ERa and ERb mRNAs and
was compared with the relative amounts in the corresponding
myometrium. A 441–base pair (bp) fragment of ERa cDNA
was amplified with use of primers (forward: 50-TGC CAA
GGA GAC TCG CTA CTG-30, reverse: 50-GGG GGC TCA
GCA TCC AAC AAG-30) corresponding to bases 896–916
and 1316–1336 of the published sequence (GenBank acces-
sion number NM 000125). A 268-bp fragment of ERb
cDNA was amplified with use of primers (forward: 50-CGA
TGC TTT GGT TTG GGT GAT-30, reverse: 50-GCC CTC
TTT GCT TTT ACT GTC-30) corresponding to bases
1400–1420 and 1648–1667 of the published sequence (Gen-
Bank accession number AB006590). Oligonucleotide
primers and Taq polymerasewere purchased from Invitrogen.
Polymerase chain reaction conditions for ERa were 94C for
5 minutes, followed by 25 cycles of 94C for 30 seconds,
60C for 30 seconds, and 74C for 30 seconds, and a final
step of 74C for 10 minutes. Polymerase chain reaction
conditions for ERb were 95C for 5 minutes, followed by
30 cycles of 95C for 30 seconds, 60C for 30 seconds, and
72C for 30 seconds, and a final step of 72C for 10 minutes.
The RT-PCR reaction products were analyzed by polyacryl-
amide gel electrophoresis (PAGE), stained with ethidium
bromide, and quantified with use of a Crossfield 5400/Rip/Vol.-, No.-,- 2008
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vices, Shefford Beds, UK). Normalized levels of ERa and
ERb mRNA were obtained by dividing the corresponding
RT-PCR reaction product densities by the respective GAPDH
product densities.Protein Preparation and Analysis
Preparation of cytosol and nuclear extracts Frozen
leiomyoma and myometrium samples were homogenized in
ice-cold TEM (10 mmol/L tris[hydroxymethyl]aminome-
thane [Tris] pH 7.4, 1 mmol/L ethylenediaminetetraacetic
acid [EDTA], 2 mmol/L Na2MO4, and 10% glycerol) (Sigma,
St. Louis, Mo)in a tissue weight–to–buffer volume ratio of
1:4 (grams per milliliter) with use of an Ultra-Turrax T25
homogenizer (Fischer Scientific, Schwerte, Germany). The
homogenate was centrifuged initially at 1,000  g for 10
minutes, and the resulting supernatant was centrifuged at
10,000  g for 60 minutes. The resulting cytosol (superna-
tant) was used to assay ER by immunoprecipitation-
PAGE-immunoblotting and ligand binding. The protein
concentration of the cytosol was measured by the Bradford
method (26).
For the preparation of the nuclear extracts, fine slices of the
leiomyoma and myometrium samples were homogenized in
ice-cold TSM (25 mmol/L Tris pH 7.5, 5 mmol/L KCl, 0.5
mmol/L MgCl2, 0.5 mmol/L dithiothreitol [DTT], 0.5
mmol/L phenylmethylsulfonyl fluoride [PMSF]) with use
of a Teflon-glass homogenizer (Thomas, Philadelphia, PA).
The nuclear fraction was pelleted, washed thoroughly with
isotonic buffer (25 mmol/L Tris pH 7.5, 5 mmol/L KCl, 0.5
mmol/L MgCl2, 0.5 mmol/L DTT, 1 mmol/L PMSF, and
0.2 mmol/L sucrose), and lysed with TET (25 mmol/L Tris
pH 7.5, 1 mmol/L EDTA, 0.1% Triton, 0.5 mmol/L DTT,
0.5 mmol/L PMSF). Nuclear debris was removed by centrifu-
gation at 55,000  g for 1 hour at 4C. The protein concen-
tration of the resulting nuclear extract (supernatant) was
measured by the method of Bradford (26).
Immunoprecipitation, PAGE, and immunoblotting Immuno-
precipitation was carried out with use of 40 mg of protein
A–Sepharose 6MB (Sigma, St. Louis, MO), mixed with 0.2
mg of the C-311 antibody against ERa (Santa Cruz Biotech-
nology, Santa Cruz, CA) in nondenaturing immunoprecipita-
tion buffer (0.05 mol/LTris pH 7.9, 1 mmol/L DTT, 0.1 mol/
L KCl, 0.1% Nonidet P-40, 20% glycerol) (Sigma), and incu-
bated for 2 hours at 4C under rotary shaking. The resin with
the bound antibody was collected by centrifugation (1,500 
g, 1 minute) and washed three times for 5 minutes with 1 mL
of ice-cold immunoprecipitation buffer; 0.5 mg of nuclear
extract protein was added, and the mixture was further
incubated for 4 hours at 4C under rotary shaking. The resin
was then washed and collected by centrifugation as above.
The pellet was resuspended in 2 sodium dodecyl sulfate
(SDS)–PAGE sample buffer and subjected to SDS-PAGE
and immunoblotting analysis, as already described (27).
Immunostaining was developed by using ECLplus (Amer-
sham Biosciences, Piscataway, NJ) and quantified by usingFertility and Sterilitya Storm 860 phosphorimager (Molecular Dynamics , Sunny-
vale, CA).
Estrogen receptor assessment by ligand binding The as-
sessment of ER in the cytosol of leiomyomas and adjacent
myometrium was carried out with use of standard Scatchard
plot analysis as previously described (28). In brief, aliquots
(150 mL; 400 mg protein) of cytosol were incubated overnight
at 4Cwith increasing concentrations (0.1–8 nmol/L in 50 mL
TEM) of tritiated 17-[2, 4, 6, 7-3H] 17b-E2 (95 Ci/mmol;
NEN) and with (50 mL of) a 1,000-fold molar excess of dieth-
ylstilbestrol in TEM (Sigma), or with (50 mL of) a 200-fold
molar excess of the ERa-selective ligand propyl pyrazole
triol (PPT) (29) in TEM, or with (50 mL of) TEM alone. After
incubation, the samples were mixed with a dextran-coated
charcoal pellet (prepared from 50 mL of 10% Norit A prein-
cubated with 0.1% dextran T70; USB Corp., Clevelana, OH)
for 20 minutes at 4C to remove free tritiated E2, Norit A–
dextran T70 was pelleted by centrifugation at 1,500  g for
10 minutes, and 200 mL of clear supernatant was removed
and counted with use of 4.2 mL of Ultima-gold XR scintilla-
tion fluid (PerkinElmer, Waltham, MA) and a Wallac 1409
DSA scintillation counter (Wallac/PerkinElmer, Waltham,
MA). The levels of total ER and ERa were obtained from
the difference in tritiated E2 binding in the absence and pres-
ence of diethylstilbestrol and PPT, respectively, and were
expressed as femtomoles (of specifically bound tritiated E2)
per milligram of protein. The protein concentration was
measured by the Bradford method (26).
Electrophoretic mobility shift assay Electrophoretic mobil-
ity shift assay (EMSA) was performed with use of the ERE
of the Xenopus vitellogenin A2 gene (vitERE), as reconsti-
tuted by annealing of the following oligonucleotides:
50-TCAAAGTCAGGTCACAGTGACCTGATCAAAGA-30
and 50-TCTTTGATCAGGTCACTGTGACCTGACTTTG
A-30. The reconstituted vitERE was end-labeled with g-32
P-adenosine triphosphate (ATP) with use of T4 polynucleo-
tide kinase, and the labeling reaction products were purified
by PAGE with use of an 8% polyacrylamide gel. Protein
DNA binding reactions were carried out by mixing 2,000
cpm of g-32P-labeled oligonucleotide with 20 mg of nuclear
extract protein in binding buffer (50 mmol/L HEPES pH
8.0, 500 mmol/L NaCl, 0.5 mol/L PMSF, 0.5 mg/mL bovine
serum albumin, 1 mmol/L EDTA, 20% glycerol) plus 1
mmol/L DTT and 150 mg/mL poly(20-deoxyinosic-20-deoxy-
cytidilic acid) sodium salt (poly(dI-dC)) (Sigma). The
reaction mixture was left at room temperature for 30 minutes,
and the samples were subsequently subjected to electrophore-
sis on a 6% polyacrylamide gel at 150V for 90minutes, dried,
and visualized by autoradiography. For the supershift assay,
the reaction mixture was incubated with antibodies to ERa
or ERb (Santa Cruz Biotechnology) for 30 minutes at 4C.
Statistical Analysis
Statistical analysis was performed with use of MedCalc
software version 7.6.0.0 (MedCalc Software, Mariakerke,
Belgium). The levels for ERa and ERb mRNA relative to3
FIGURE 1
Estrogen receptor levels (median values) in the
cytosol of leiomyomas (LEIO) compared with normal
myometrium (MYOM) from 35 patients operated on
for symptomatic fibroids. Median values of ER levels
in leiomyoma and the corresponding myometrium
samples, as assessed by Scatchard plot analysis
with use of tritiated E2, were calculated by using the
ARTICLE IN PRESSGAPDH mRNA in leiomyomas and the corresponding nor-
mal myometrium were compared with use of the paired sam-
ples t-test (and confirmed by the Wilcoxon paired samples
test, i.e., the nonparametric equivalent of the paired samples
t-test). For comparing the ER status of leiomyomas and
normal myometrium, the nonparametric Wilcoxon paired
samples test was used, because the data were not normally
distributed, and results were plotted with use of a box-
and-whisker graph.nonparametric Wilcoxon paired samples test,
expressed as femtomoles of ER per milligram of
cytosol protein and plotted with use of a box-and-
whisker graph. The boxes contain the values
between the upper (75th percentile) and lower (25th
percentile) quartiles, the lines across the boxes
correspond to the medians, and the whiskers extend
to the highest and lowest values, excluding outliers
(open square) and extreme values (filled squares).
*Significantly different compared with myometrium
(P< .05).RESULTS
Patient Characteristics
Biopsy samples of uterine leiomyomas and adjacent myome-
trium during the follicular phase of their cycle from 35
women who underwent myomectomy or total abdominal
hysterectomy for uterine fibroids were included in this study.
The mean age of the patients was 45.7  2.9 years (95%
confidence interval 44.7–46.7 years), the mean body mass
index was 28.1  1.3 kg/m2 (95% confidence interval
27.7–28.6 kg/m2), and mean parity was 1.9  0.7 (95%
confidence interval 1.7–2.2).Bakas. Estrogen receptors a and b in fibroids. Fertil Steril 2008.Estrogen Receptor Status of Leiomyomas and Normal
Myometrium
Initially we studied tritiated E2 binding of the ER in the cyto-
sol of leiomyomas and the adjacent myometrium with use of
Scatchard plot analysis. We found that the level of ER in the
cytosol of leiomyomas (median level, 67 fmol/mg protein)
was significantly higher (Wilcoxon paired samples test;
P<.002) compared with that of myometrium (median level,
30 fmol/mg protein) (Fig. 1). Then we tried to use PPT, which
reportedly exhibits a relative (to E2) binding affinity for ERa
(RBAa) that is much higher than that (RBAb) for ERb (29),
to estimate the fraction of E2 binding of ER that could be at-
tributed to ERa alone, with inconsistent results. The reason
for this could be that the ERa-to-ERb binding selectivity of
PPT, as determined with use of purified ERa and ERb and
a fluorescence polarization assay previously described (27,
30), was found not higher than 100 (RBAa ¼ 50.2  2.4,
RBAb ¼ 1.4  0.3, RBAa/RBAb ¼ 36; RBAa and RBAb
of E2 are set equal to 100). This caused substantial inhibition
of E2 binding of purified ERb by PPTat concentrations of the
ligand capable of inhibiting E2 binding of purified ERa only
partially (data not shown), which rendered the estimation of
the fraction of ERa in mixtures with ERb with use of PPT
fairly inaccurate.Estrogen Receptor a and ERb Gene Expression of
Leiomyomas and Normal Myometrium
Next we examined whether the higher level of ER in the
myoma cytosol was due to an increase in the level of gene
expression of ERa, ERb, or both. We therefore determined
the levels of mRNA of ERa and ERb in the myomas and
the adjacent myometrium using semiquantitative multiplex
RT-PCR. To account for differences during the reverse4 Bakas et al. Estrogen receptors a and b in fibroidstranscription (RT) step, GAPDH cDNA was also amplified
and used as a reference standard in all the samples (Fig. 2).
Unlike the levels of cytosolic ER we determined by tritiated
E2 binding, the levels of mRNA of ERa and ERb relative to
those of GAPDH, deduced as described in Materials and
Methods, were distributed quite normally. The mean ratio
of mRNA levels of ERa relative to GAPDH was 1.7  1.7
(95% confidence interval 1.1–2.3) in the myometrium and
3.2  2.4 (95% confidence interval 2.4–4.1) in the myomas.
The mean level of ERamRNA in the myomas was found 1.9
times higher (paired samples t–test; P<.0001) than in the ad-
jacent myometrium. Using a similar approach we found that
the mean ratio of mRNA levels of ERb relative to GAPDH
was 1.0  0.5 (95% confidence interval 0.8–1.3) in the
myometrium and 1.8  1.2 (95% confidence interval 1.4–
2.3) in the myomas. The mean level of ERb mRNA in the
myomas was found 1.8 times higher (paired samples t–test;
P<.0025) than in the myometrium. Thus, it appears thatVol.-, No.-,- 2008
FIGURE 2
Estrogen receptor a and ERb mRNA levels in
leiomyomas and the corresponding normal
myometrium, as compared with the respective
GAPDHmRNA levels. Estrogen receptor a, ERb, and
GAPDH mRNA levels in the myometrium (M) and the
corresponding leiomyoma samples (L) from each
individual patient were obtained by semiquantitative
multiplex RT-PCR. Typical ethidium bromide–
stained gels of the RT-PCR reaction products from
the samples of 20 patients are shown.
Bakas. Estrogen receptors a and b in fibroids. Fertil Steril 2008.
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myomas compared with myometrium is due to similar
increases in the level of mRNA of ERa and ERb.Deoxyribonucleic Acid–binding Activity of Leiomyoma and
Myometrial ER
To find whether and how up-regulation of myoma ER affects
the DNA-binding activity of the receptor we carried out
comparative EMSA analysis of the ER of myomas and the
respective myometrial samples using the vitERE as bait.
We invariably observed that vitERE binding of protein in
nuclear extracts from leiomyoma samples was higher as
compared with normal myometrium. Then we focused on
the samples in which up-regulation of ERa mRNA relative
to ERb mRNA was most noticeable (e.g., samples 5 and 10
of Fig. 2). Initially we examined whether the higher level
of ERa mRNA expression of these leiomyomas was accom-
panied by a higher level of the receptor in the nuclear extract.
Immunoprecipitation and immunoblotting analysis using
ERa-specific antibodies and quantification of ERa by phos-
phorimaging revealed that leiomyoma levels of ERa from,
for example, samples 5 and 10 were 9.3-fold and 6.2-fold
higher, respectively, as compared with the respectivemyome-Fertility and Sterilitytrial levels (Fig. 3A). Next we compared vitERE binding of
proteins in the nuclear extracts of leiomyoma and the respec-
tive adjacent myometrium. Quantification of the vitERE-
protein complexes using phosphorimaging detected
11.2-fold and 7.8-fold higher vitERE binding activity in
leiomyoma samples 5 and 10, respectively, compared with
the adjacent myometrium (Fig. 3B; lanes 1–4). Supershifting
analysis of the ERE-binding activity of leiomyoma sample 10
and the respective myometrium using antibodies specific for
ERa and ERb followed by phosphorimaging revealed that the
participation of ERa in the ER-vitERE complexes exceeded
that of ERb by 9.4-fold (Fig. 3B; compare the supershifted
bands in lanes 5 and 6), as compared with 2.2-fold in the
adjacent myometrium (Fig. 3B; compare the supershifted
bands in lanes 7 and 8). Thus, the 6.2-fold increase in the
level of ERa in myoma sample 10 compared with the
adjacent myometrium (Fig. 3A) is faithfully reflected by
a comparable increase in the participation of ERa in ER-
vitERE complexes (Fig. 3B; compare the supershifted bands
in lanes 5 and 8). Similarly, the increased participation of
ERb in the ER-vitERE complexes in myoma sample 10 com-
pared with the adjacent myometrium (Fig. 3B; compare
the supershifted bands in lanes 6 and 7) faithfully reflects
the mean 1.8-fold increase in the level of ERb mRNA in the
myomas compared with the myometrium reported above.
Interestingly, Fig. 3B shows, in addition, that ER-vitERE
complexes containing ERa alone occurred to a much higher
extent with myoma than with myometrial ERa (Fig. 3B;
compare the nonsupershifted bands in lanes 6 and 7).DISCUSSION
Estrogens regulate a variety of physiologic processes in many
different tissues and organs. They act predominantly through
the two hormone-binding forms of ER, ERa and ERb, both of
which function as ligand-dependent regulators of transcrip-
tion by binding to enhancer elements in the promoter of estro-
gen target genes in heterodimeric or homodimeric form
(9–11). Uterine leiomyomas express ERa and ERb, and their
development is known to be estrogen dependent (4–6), but
the molecular basis of this dependency is not clearly under-
stood. In the present study we used myomas and adjacent
myometrium from 35 women at the follicular phase of their
menstrual cycle to examine whether ERamRNA and protein
levels are up-regulated in the myomas compared with the
adjacent myometrium and how this up-regulation might
impact the ERE-binding activities of ERa and ERb. We
found that the level of expression of both ERa and ERb
mRNA is by and large higher in leiomyomas compared
with normal myometrium (Fig. 2), causing the level of ER
to increase accordingly (Fig. 1), and that the abundance of
ERa relative to ERb can increase in leiomyomas compared
with the myometrium to a level that is high enough to allow
leiomyoma ERa to bind to the vitERE as a homodimer, as
well as a heterodimer with ERb (Fig. 3). Specifically, the
data of Figure 3B suggest that up-regulation of ERa in
myoma sample 10 (Fig. 3A) caused the receptor to bind to5
FIGURE 3
Protein levels and DNA-binding status of ERa in leiomyomas and the corresponding normal myometrium. (A)
Representative immunoprecipitation, PAGE, and immunoblotting analysis of ERa in nuclear extracts from normal
myometrium (M) and leiomyoma (L) samples no. 5 (5M and 5L) and no. 10 (10M and 10L), selected for their high
ERa-to-ERbmRNA expression ratio (see samples numbered in Fig. 2). (B) vitERE binding of protein in the nuclear
extracts from normal myometrium and leiomyoma samples no. 5 and no. 10, as assessed by EMSA (lanes 1 vs. 2
and 3 vs. 4, respectively). Supershifting of vitERE-binding of protein in the nuclear extracts from normal
myometrium and leiomyoma sample no. 10, as assessed by EMSA in the presence of antibodies to ERa (a-ERa,
lanes 5 and 8) and ERb (a-ERb, lanes 6 and 7). *Significantly different compared with 5M (P< .05; t-test).
#Significantly different compared with 10M (P< .05; t-test). Ab ¼ antibodies.
Bakas. Estrogen receptors a and b in fibroids. Fertil Steril 2008.
ARTICLE IN PRESSthe ERE as a homodimer (not supershifted with antibodies to
ERb), as well as a heterodimer with ERb, and that this is not
the case with ERa in the corresponding normal myometrium.
Notably, formation of an ERE-binding homodimer of ERa
occurred in spite of the participation of leiomyoma ERb in
ER-vitERE complexes being nearly twice as high as that of
myometrial ERb, suggesting that the formation of ERE-bind-
ing homodimers of ERa depends on the ERa-to-ERb ratio
rather than the individual amounts of the two ER subtypes.
That ERb is usually up-regulated in the myomas compared
with the myometrium is further substantiated by the data of
Figure 2. Thus, it appears that the formation of ERE-binding
homodimers of ERa is most likely the result of higher up-reg-
ulation of ERa compared with ERb rather than the result of
down-regulation of ERb during the myometrium-to-myoma
transition.
Estrogen receptor a is considered to be a key player in the
development of uterine fibroids, because ERa mRNA and
protein levels are often up-regulated in fibroids compared6 Bakas et al. Estrogen receptors a and b in fibroidswith myometrium (19, 22). In line with this notion, adenovi-
rus-mediated expression of a dominant negative ERa was
recently shown to inhibit tumor growth in nude mice (6). In
addition, ERa is considered to be a key player during pro-
gression of benign mammary proliferative disorders to inva-
sive carcinomas. Recent evidence suggests, however, that
a high ERa-to-ERb ratio rather than the level of ERa alone
is what characterizes those cases of mammary hyperplasia
of the usual type that are likely to progress to breast cancer
(16). In fact, there is ample evidence that, although ERa
expression is maintained in breast cancer compared with
benign tumors or normal mammary tissue, ERb expression
is decreased (31). Interestingly, work with HC11 immortal-
ized mammary epithelial cells has revealed that, although
E2 promotes cell growth through ERa, at the same time it
causes cells to undergo apoptosis through ERb (15). Thus,
it appears that the establishment of a high ERa-to-ERb ratio,
as the result of down-regulation of the expression of ERb
during progression of benign mammary tumors to breast
cancer, is somehow associated with enhancement of tumorVol.-, No.-,- 2008
ARTICLE IN PRESSgrowth, and this could reflect stimulation of ERa-dependent
cell proliferation, suppression of ERb-dependent cell death,
or both. The physiologic significance of the disproportionate
up-regulation of the ERa-to-ERbmRNA ratio during uterine
fibroid development (e.g., Fig. 2, sample 5), and the relative
abundance of ERa over ERb that is likely to result, as regards
proliferation and survival of myoma smooth muscle cells, is,
however, unexplored.
It has been reported that ERa and ERb can form hetero-
dimers that bind DNA with an affinity similar to that of
ERa homodimers and greater than that of ERb homodimers
(10); that ERb can regulate gene expression in a ligand-
independent manner (17, 32); and that the ERE-dependent
transcriptional activity of ERa in the presence of E2 is
negatively modulated by ERb, which thus appears to act as
a dominant suppressor of ERa (30, 32). The transcriptional
activity of ERa through other transcription factors in the
promoter of estrogen target genes also is modulated nega-
tively by ERb. Most important, E2 activation of cyclin D1
gene expression through ERa is completely inhibited by
ERb (33). The opposing action and dominance of ERb over
ERa in E2 activation of both ERE-dependent and AP1-depen-
dent gene expression supports a role for ERb as a dominant
negative inhibitor of the proliferative and antiapoptotic
effects of E2 through ERa. In line with this notion, it has
been proposed that the modulation of ERa-dependent cyclin
D1 expression by ERb could be defective in leiomyomas
(34). Our data provide a mechanistic basis as to how this
might come about, because they show that in leiomyomas
with a high ERa-to-ERb ratio, formation of ERa homo-
dimers is increased substantially, and this may cause the
opposing action of ERb on, for example, ERa-mediated
activation of cyclin D1 gene expression to decrease accord-
ingly, with potentially pronounced implications as regards
tumor growth. In addition, our data indicate that a substantial
increase in the fraction of ERa homodimers, as detected with
use of vitERE as bait, could be the molecular determinant
that differentiates fast-growing myomas from stationary
ones. A study is currently in progress to test this hypothesis.
No effective medical treatment is available presently to
women who have symptomatic fibroids and want to avoid
surgery (35). Because leiomyomas may depend on an ERa-
to-ERb ratio higher than normal for growth in the presence
of estrogen, agents causing down-regulation of ERa and/or
up-regulation of ERb could be used against fibroids. Interest-
ingly, indole-3-carbinol, a constituent of Brassica vegetables
reportedly endowed with potent anticancer activity in rodent
models of carcinogenesis (36), was recently shown to down-
regulate ERa expression without altering ERb expression of
MCF-7 breast cancer cells and to cause the levels of ERE-
bound ERa and ERb to decrease and increase, respectively,
and the stimulation of the proliferation of the cells by E2 to
drop as a consequence (37). Thus, agents that can decrease
the inherently high ERa-to-ERb ratio of MCF-7 cells may
also inhibit the estrogen-dependent proliferation of these
cells, apparently by improving promoter occupancy of ERFertility and Sterilitytarget genes by ERb relative to ERa. Whether such agents
could have an impact on the growth of fibroid smooth muscle
cells, which are known to express ERb as well as ERa (18), is
presently a matter of conjecture.REFERENCES
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